Targeted radioimmunotherapy, including yttrium 90-labeled ibritumomab tiuxetan (Zevalin®) and iodine 1131 tositumomab (Bexxar®), has the potential to increase the cure rate for patients with CD20+ B-cell malignancies who are undergoing autologous hematopoietic stem cell transplantation. The results of phase I and II trials suggest that radioimmunoconjugates can be safely combined with high-dose chemotherapy, although the optimal approach remains to be established. This review focuses on the use of 90Y ibritumomab tiuxetan combined with high-dose chemotherapy in the setting of autologous hematopoietic stem cell transplantation.
|Original language||English (US)|
|Issue number||SUPPL. 1|
|State||Published - Oct 2004|
- Autologous stem cell transplantation
- Targeted therapy
ASJC Scopus subject areas
- Cancer Research